Creating a new treatment to prevent complications in Hemophilia A
Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A
This study is testing a new treatment for people with Hemophilia A that aims to help their bodies accept Factor VIII without creating harmful antibodies, making it safer and more effective than current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10815822 on NIH RePORTER |
What this research studies
This research focuses on developing a new form of Factor VIII (FVIII) that aims to prevent the development of inhibitors in patients with Hemophilia A, a serious bleeding disorder. The approach involves using a tolerogenic version of FVIII combined with a special nanoparticle to help the immune system accept the treatment without producing harmful antibodies. By administering this new treatment either orally or intravenously, the researchers hope to reduce the risk of complications associated with traditional FVIII therapies. This innovative method could provide a safer and more effective option for patients who are at risk of developing inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Hemophilia A who are at risk of developing inhibitors to Factor VIII.
Not a fit: Patients who do not have Hemophilia A or those who have already developed inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of complications and improve the quality of life for patients with Hemophilia A.
How similar studies have performed: While this approach is innovative, previous research has shown promise in using tolerogenic therapies for other autoimmune conditions, suggesting potential for success in this area as well.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Balu-Iyer, Sathy Venkat — State University of New York at Buffalo
- Study coordinator: Balu-Iyer, Sathy Venkat
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.